Sun Pharma Advanced Research Company’s record turns on a single non-cash item: a ₹1,840 crore USFDA voucher that delivered 98% of FY26 revenue and a reported profit of ₹1,553 crore. Behind that gain, the core R&D business has consumed over ₹1,097 crore in operating cash in four years, and the company remains funded by repeated promoter-group support and equity infusions.
Key findings
- A one-time voucher gain masks deep cash losses
Major- The Company recognised ₹1,840 crore from a Priority Review Voucher granted by the USFDA on 3 February 2026 and sold on 30 April 2026, accounting for 98% of FY26 revenue of ₹1,879 crore. Excluding the voucher, customer-contract revenue fell to roughly ₹39 crore from ₹72 crore in FY25 and ₹76 crore in FY24. Operating cash flow over the four years to FY26 was negative ₹1,097 crore against a cumulative reported profit of ₹601 crore, and Sloan accruals reached 143% in FY26, showing an extreme gap between profit and cash. - Operating cash flow has been deeply negative for at least six years
Major- The auditor’s CARO report, a mandatory check on financial health, recorded cash losses in every year from FY21 through FY25: ₹333.54 crore in FY25, ₹372.39 crore in FY24, ₹214.1 crore in FY23, ₹193.92 crore in FY22, and ₹140.37 crore in FY21. Cash and equivalents fell from ₹5.06 crore at 31 March 2024 to ₹1.19 crore at 31 March 2025. The going-concern assessment in FY24 relied on unutilised credit limits guaranteed by a promoter-group entity and a financial support letter from the same group. - The company depends on promoter-group entity Shanghvi Finance for credit and guarantees
Major- The outstanding corporate guarantee from Shanghvi Finance Private Limited rose from ₹200 crore at 31 March 2025 to ₹545 crore at 31 March 2026. In the same year, the board approved a preferential warrant issue of up to ₹600 crore to Shanghvi Finance; the warrants were allotted on 19 May 2026 with 25% of the issue price received. A working-capital loan from Kotak Mahindra Bank and ICICI Bank is secured by a Shanghvi Finance guarantee, and total reported borrowings stood at ₹556 crore at 31 March 2026, all short-term. - FY26 secretarial audit notes listing-rule fines, but governance report says no penalties
Minor- The FY26 Secretarial Audit Report records an inadvertent lapse in complying with SEBI LODR Regulation 17(1A) regarding the appointment of Mr. Venkateswarlu Jasti from 19 May 2025, and states that NSE and BSE levied fines. The FY26 Corporate Governance report states that no penalties were imposed by any stock exchange or statutory authority during the last three financial years. - Audit opinions are clean; two FY24 IT exceptions were resolved
Minor- The standalone audit opinion was unqualified every year from FY21 through FY26. In FY24, the auditor reported that daily backup of books was not kept on servers physically in India for 66 days and the audit-trail feature was not enabled for direct database changes. Both exceptions were resolved in FY25 and FY26, with the auditor confirming the audit trail operated throughout both years. - The company added two US subsidiaries in quick succession after years of having none
Minor- SPARC had no subsidiaries from at least FY20 through FY23. It incorporated SPARCLIFE Inc. in Delaware on 25 September 2023, which generated turnover of ₹26.74 crore in its first partial year. A second subsidiary, Genokine Biotech Limited, was incorporated on 4 July 2025 as an asset-specific vehicle for the SCO-155 program. - Tax and regulatory disputes are routine in size and stage
Minor- Disputed income-tax demands fell from ₹88.48 crore at 31 March 2024 to ₹32.89 crore at 31 March 2025. Amounts paid under protest stood at ₹28.58 crore for income tax and ₹1.73 crore for sales tax and other matters at 31 March 2026. The Company states it does not expect the outcome of pending litigations to have a material adverse impact on its financial condition, results, or cash flows.
What to watch
- Warrant conversion. The balance 75% (₹116.85 per warrant) on the 3,85,10,000 warrants held by Shanghvi Finance is payable within 18 months from the 19 May 2026 allotment date.
- Promoter loan repayment. An unsecured term loan from a promoter-group entity is due on 30 December 2026.
- Aged receivables. 2.05 crore of trade receivables were credit-impaired and outstanding for over two years as of 31 March 2025, with a further 4.27 crore in the 1-2 year bucket.
Bottom line: This is a pre-revenue R&D company whose reported profit in FY26 is almost entirely a non-cash voucher gain. The underlying business consumes cash at a pace that has required repeated promoter support, and the balance sheet is structurally tied to Shanghvi Finance through guarantees, credit lines, and a fresh warrant issue. The audit opinions are clean and the governance lapses are procedural, but the going-concern arithmetic depends on the promoter group’s continued willingness to fund. Watch the warrant conversion and the December 2026 loan repayment.